Medicare “negotiation” proposals threaten Americans’ access to medicines

While nearly 90% of seniors and people with disabilities report that they are very satisfied with their Medicare Part D prescription drug coverage, they also acknowledge concerns with rising...
Read More
3 things that support robust biopharmaceutical research and development

Rapid advances in scientific discovery have ushered in a new era of medicine, transforming our ability to treat, and in some cases cure, many of the most challenging diseases, including cancer, rare...
Read More
Watch: Building trust and enhancing clinical trial diversity

On June 22, during The Atlantic’s Health Equity Summit, PhRMA hosted a conversation on clinical trial diversity. PhRMA Chief Operating Officer Lori Reilly and Genentech Vice President and Chief...
Read More
IP Explained: How does the U.S. patent process work?

Have you ever used a Teflon-coated pan or hit a golf ball down the fairway? Had a friend or family member receive treatment with a new medication? All these products were developed because patents...
Read More
Building a better health care system: A conversation with Mark Reisenauer, President of Astellas US

Our industry continues to work tirelessly to combat the COVID-19 virus by developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. As we continue our efforts to...
Read More
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities

We are in a new era of medicine where groundbreaking biopharmaceutical research and development is transforming medicine, but these innovations are meaningless if they don’t reach patients, including...
Read More
New PhRMA Scholars program provides support to exceptional college-bound DC students

As part of our continued efforts to promote diversity, equity and inclusion, we’re excited to announce the PhRMA Scholars program and the exceptional students who received this year’s awards.
Read More
Americans 12 years of age and older are eligible for COVID-19 vaccines

Last month, the U.S. Food and Drug Administration (FDA) granted an expansion of an emergency use authorization on one of the COVID-19 vaccines allowing Americans 12-15 years of age and older to be...
Read More
Researchers to shine light on biopharmaceutical R&D with policymakers

Today, biopharmaceutical researchers from PhRMA member companies are meeting virtually with members of Congress and staff to share their stories of transforming game-changing scientific discoveries...
Read More
PhRMA hosts first stakeholder workshop on clinical trial diversity

This week, 500+ health care and community members from over 150 organizations came together at PhRMA’s first stakeholder workshop focused on improving diversity in clinical trials. At the virtual...
Read More
How research evolves and brings new hope to patients

Before medicines can be made available to patients, they often begin as ideas that are based on newly discovered molecules and cells, strange phenomena or little-understood processes in the body. The...
Read More
Coming together to fight COVID-19: A conversation with Barry Greene, CEO of Sage Therapeutics

This year, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. A key...
Read More
New reports shed light on key facts about medicines and affordability

A recently released report by IQVIA – an independent organization specializing in health care research – provides new data showing prices for brand medicines went down last year. The report offers...
Read More
Continued R&D into Alzheimer’s disease means hope for patients, families and caregivers

More than 6 million Americans, most of them age 65 or older, live with Alzheimer’s disease, a devastating degenerative brain disease and the most common form of dementia. After heart disease and...
Read More